CareDx, Inc.
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Open CDNA dashboard ↗So-Young International Inc. American Depository Shares
So-Young International Inc. operates an online platform for consumption healthcare services in the People's Republic of China. The company offers So-Young Mobile App that offers users access to medical aesthetic knowledge, community support and reservation options for treatment with medical professionals, and medical aesthetic institutions; Weixin mini program to explore treatment options, check prices, schedule appointments, participate in online consultations, and track follow-ups; and medical aesthetic community content through its website soyoung.com. Its aesthetic centers offer non-invasive and minimally invasive procedures, including device-based options, such as thread lifts, intense pulsed light, ultrasound facelifts, picosecond lasers, and body contouring treatments, as well as injectable treatments, including skin boosters, hyaluronic acid-based products, botox, and type I and type III collagen. In addition, the company engages in the research and development, production, sale, and distribution of light therapy devices, including excimer laser systems, UV excimer therapy devices, LED and red-light therapy systems, and advanced laser and intense pulsed light technologies; surgical laser devices, including carbon dioxide laser machines, multi-wavelength and semiconductor laser systems, and hydrodynamic-assisted liposuction systems, as well as pneumatic liquid spray devices. Further, it offers injectable products; sales and technical, maintenance, installation, operational training, error reporting, maintenance, and equipment packaging services; consumption healthcare services, including dermatology, dentistry and orthodontics, physical examinations, gynecology, and postnatal care; reservation services; and content management through beauty diaries, short-form videos, treatment reviews, featured articles, and chat messages. The company was founded in 2013 and is headquartered in Chaoyang, China.
Open SY dashboard ↗